Weekly COVID-19 Vaccination Dashboard | COVIDVaxView | CDC The Weekly COVID-19 Vaccination Dashboard is designed to share preliminary weekly in-season COVID-19 vaccination information, including vaccination coverage estimates and intent for vaccination, using a variety of data sources including telephone surveys, healthcare claims databases, electronic medical records, and immunization information systems (IISs)
COVID-19 vaccine tracker and landscape - World Health Organization (WHO) The COVID-19 vaccine tracker: Provides summary tables of COVID-19 vaccine candidates in both clinical and pre-clinical development; Provides analysis and visualization for several COVID-19 vaccine candidate categories; Tracks the progress of each vaccine from pre-clinical, Phase 1, Phase 2 through to Phase 3 efficacy studies and including Phase
COVID-19 vaccines | WHO COVID-19 dashboard - datadot Vaccinated with a complete COVID-19 primary vaccine series: Having received the number of doses of a COVID-19 vaccine corresponding to that product's primary series, as per its product-specific use authorization in the country where it was administered The number of doses constituting a primary series varies by product and by country
CDC COVID Data Tracker - Centers for Disease Control and Prevention CDC’s home for COVID-19 data Visualizations, graphs, and data in one easy-to-use website Data Tracker Home Trends Maps Hospitalizations Deaths Emergency Department Visits Vaccination Distribution Coverage Vaccine Effectiveness Variants Genomic Surveillance Traveler-Based Genomic Surveillance Pediatric Seroprevalence Other COVID-19
2024–2025 COVID-19 Vaccination Guidance - Centers for Disease Control . . . 2024–25 Moderna COVID-19 Vaccine Vaccine type: mRNA | Do NOT use any previously available Moderna COVID-19 vaccine products If current age is: And the COVID-19 vaccination history is: Then: Administer: 6 months through 4 years† Unvaccinated (0 doses) Give a 2-dose initial series • Dose 1 now • Dose 2 at least 4–8 weeks after Dose 1 ‡
COVID-19 Vaccine: What You Need to Know - Johns Hopkins Medicine How is the 2024–25 COVID-19 vaccine different from previous COVID-19 vaccines? For fall winter 2024–25, the updated COVID-19 vaccines target newer variants of the virus The vaccines created by Pfizer-BioNTech and Moderna both target the KP 2 strain, part of the larger FLiRT family of variants that have spread throughout the spring and summer
COVID-19 vaccines - World Health Organization (WHO) WHO has published the target product profiles for COVID-19 vaccines, which describes the preferred and minimally acceptable profiles for human vaccines for long term protection of persons at high ongoing risk of COVID-19, and for reactive use in outbreak settings with rapid onset of immunity
Coronavirus disease (COVID-19): Vaccines and vaccine safety Yes, all WHO emergency-use listed or prequalified COVID-19 vaccines provide protection against severe disease and death from circulating COVID-19 variants Any of the approved COVID-19 vaccines can be used either for the initial series or revaccination Vaccination should not be delayed in anticipation of newer versions of the COVID-19 vaccine
VACCINE INFORMATION FACT SHEET FOR RECIPIENTS AND CAREGIVERS . . . - Pfizer Pfizer-BioNTech COVID-19 Vaccine authorized under Emergency Use Authorization (EUA) for individuals 12 years of age and older, when prepared according to their respective instructions for use, can be used interchangeably 2 COMIRNATY (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech